ARS Pharmaceuticals, Inc. SPRY
Set alert
3.05 USD -0.33 -9.76%
At close
3.01 -0.04 -1.31%
Pre-market · Nov 3, 8:18 AM ET
2.91 Day range 3.48
2.91 52-week range 13.15
- YTD
- -73.82%
- 1 year
- -64.62%
- Open
- 3.40
- Prev close
- 3.38
- Mkt cap
- 303.31M
- Vol
- 2.13M
- Avg vol
- 1.65M
- EPS
- -2.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.91
- High
- 3.48
- Forward P/E
- -11.01
- Beta
- 0.83
- Short ratio
- 13.70
- Inst. own
- 95.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2026
- 50-d avg
- 8.64
- 200-d avg
- 9.38
- 1y target
- 28.80
3M chart
Events in this range
- Aug 13, 2026Earnings: —; estimate -0.47655; surprise —%
Signals (15)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| MACD: Sell Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| RSI: Oversold | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Analyst view
Consensus: none
Price target (mean) 28.80 +844.3% upside
Now 3.05
- Target (low)
- 25.00
- Target (mean)
- 28.80
- Target (high)
- 32.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 7
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.53 | -0.61 – -0.47 | -0.46 | -15.2% | 31.53M | +100.6% | 3 |
| Next quarter | -0.33 | -0.40 – -0.20 | -0.52 | +36.5% | 51.31M | +57.9% | 3 |
| Current year | -1.76 | -2.05 – -1.45 | -1.74 | -1.1% | 149.35M | +77.2% | 4 |
| Next year | -0.9575 | -1.41 – -0.44 | -1.76 | +45.6% | 273.65M | +83.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Sep 4, 2025 | Roth Capital | Initiated | — | Buy |
| Mar 7, 2025 | Scotiabank | Initiated | — | Sector Outperform |
| Jan 14, 2025 | Raymond James | Maintained | Strong Buy | Strong Buy |
| Jan 13, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Oct 8, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 20, 2024 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 16, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 9, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 20, 2024 | Cantor Fitzgerald | Initiated | — | Overweight |
| Aug 13, 2024 | Raymond James | Upgrade | Outperform | Strong Buy |
| Jul 25, 2024 | Raymond James | Initiated | — | Outperform |
| Mar 11, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 5, 2024 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Nov 13, 2023 | Wedbush | Maintained | Outperform | Outperform |
| Sep 21, 2023 | Wedbush | Maintained | Outperform | Outperform |
| Sep 20, 2023 | William Blair | Downgrade | Outperform | Market Perform |
| Aug 14, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 21, 2023 | Wedbush | Maintained | Outperform | Outperform |
| May 18, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| May 12, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| May 10, 2023 | Wedbush | Reiterated | — | Outperform |
| Jan 31, 2023 | Wedbush | Initiated | — | Outperform |
| Jan 4, 2023 | William Blair | Initiated | — | Outperform |
| Dec 13, 2022 | SVB Leerink | Initiated | — | Outperform |